MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report.

ABSTRACT:

Background

Capmatinib, a potent and selective mesenchymalepithelial transition factor (MET) inhibitor, is an effective treatment option for non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations or gene amplification. However, the mechanisms that confer resistance to capmatinib remain elusive. Here, we present a case of primary resistance to capmatinib in a MET-amplified NSCLC patient which was conferred by concurrent MYC amplification.

Case description

Capmatinib was administered as first-line treatment in an 82-year-old MET-amplified [gene copy number (GCN) 13.5] and MET overexpressed (immunohistochemical staining 3+/3, >50%) NSCLC patient. However, the tumor rapidly progressed and showed primary resistance to capmatinib

SUBMITTER: Choi W 

PROVIDER: S-EPMC9554684 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature